Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT06413056
Other study ID # micafungin in neonates
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date October 20, 2022
Est. completion date August 30, 2023

Study information

Verified date May 2024
Source Ain Shams University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The incidence of fungal infection has increased dramatically over the past few decades.This is due to increase in survival rates of preterm neonates, advances in medical technology and drug therapy, broad spectrum antibiotics and parenteral nutrition . The resistance to antifungal agents has increased. This study will assess the efficacy of micafungin versus amphotericin B in neonates with positive fungal culture.


Description:

Neonatal candidiasis is associated with significant mortality and morbidity and high rates of neuro-developmental impairment on follow up Prevalence of invasive fungal infection (IFI) has increased in neonates during the last two decades due to increased survival rate even in the extremely premature neonates. Candida albicans and Candida parapsilosis are responsible for the majority of candidiasis in the neonatal intensive care unit (NICU) According to the European Society for Clinical Microbiology and Infectious Diseases (ESCMID)guidelines published in 2012, Micafungin, amphotericin B deoxycholate, and fluconazole are recommended as first line treatment of invasive candidiasis in neonates Currently, fluconazole and micafungin are among the most frequently used antifungal agents for the treatment of neonatal invasive candidiasis High dose of micafungin (8 to 15 mg/kg/day) can be used with neonates and infant with invasive candidiasis In this study we will explore the effectiveness and safety of micafungin for treatment of candidiasis after fluconazole for preterm neonates with invasive fungal infection and to compare it with amphotericin B.


Recruitment information / eligibility

Status Completed
Enrollment 56
Est. completion date August 30, 2023
Est. primary completion date May 20, 2023
Accepts healthy volunteers No
Gender All
Age group 1 Day to 28 Days
Eligibility Inclusion Criteria: - Patient less than 36 weeks gestational age - started fluconazole either prophylactic or therapeutic dose - and blood culture is positive for fungal infection. Exclusion Criteria: - Any neonate with hepatic dysfunction for any cause (hepatitis or hepatic failure), or with elevation in AST, ALT, alkhaline phosphatase - Any neonate hypertensive, neutropenic, thrombocytopenic - Any neonate with elevated renal function - Any neonate with arrythmia

Study Design


Intervention

Drug:
Micafungin
Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups. Will receive either micafungin or amphotericin B
Amphotericin B
Preterm neonate with fungal infection provened by fungal culture and who received fluconazole for at least one week will be divided into two groups.

Locations

Country Name City State
Egypt Ain Shams University Hospitals Cairo Abbassia

Sponsors (1)

Lead Sponsor Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

Outcome

Type Measure Description Time frame Safety issue
Primary resolution of fungal infection negative blood culture 14 days
Secondary complication drug complications one month
Secondary morbidity hospital stay one month
Secondary mortality death one month
See also
  Status Clinical Trial Phase
Completed NCT04200807 - Non-invasive Measurement of Neonatal Central and Peripheral Hemodynamics
Recruiting NCT05695196 - Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant Phase 1
Completed NCT01729000 - Study to Determine if Gloving in Addition to Hand Hygiene Will Prevent Invasive Infections and Necrotizing Enterocolitis N/A
Completed NCT03247920 - Reduction of Intravenous Antibiotics In Neonates Phase 4
Completed NCT02486783 - Infection, Sepsis and Meningitis in Surinamese Neonates N/A
Recruiting NCT06194396 - Effect of Chlorhexidine Versus Alcohol on Infections in Neonates N/A
Active, not recruiting NCT05343403 - Parental Participation on the Neonatal Ward - the neoPARTNER Study
Recruiting NCT04416373 - COVID-19 and Pregnancy Outcomes
Completed NCT01540162 - Experience of Mutaflor Suspension Use in Preterm Infants for Immunity Improvement N/A
Withdrawn NCT03673566 - Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - CHMCO N/A
Completed NCT04883801 - Clinical Outcomes of Newborns Born to Pregnant Women With and Without COVID-19
Terminated NCT05379452 - Outcomes of Neonates Born to Mothers With SARS-CoV-2 Infection in Shanghai
Active, not recruiting NCT04718220 - Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19 N/A
Not yet recruiting NCT06102044 - Zinc Supplementation for Young Infants With Clinical Severe Infection in Tanzania Phase 3
Active, not recruiting NCT04433364 - COPE - COVID-19 in Pregnancy and Early Childhood
Completed NCT03383211 - Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
Completed NCT04893343 - Antibiotic Use in a Neonatal Intensive Care Unit Practicing Integrative Medicine
Withdrawn NCT03673579 - Clinical Evaluation of the "NICU Clinical Decision Support Dashboard" - MHSB N/A
Completed NCT04206878 - Evaluating the Feasibility of Point of Care Birth Testing in Eswatini
Recruiting NCT05743816 - Neonatal Antimicrobial Resistance and Outcome